79 related articles for article (PubMed ID: 15951300)
1. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels.
Goerttler PL; März E; Johansson PL; Andreasson B; Kutti J; Moliterno AR; Marchioli R; Spivak JL; Pahl HL;
Haematologica; 2005 Jun; 90(6):851-3. PubMed ID: 15951300
[TBL] [Abstract][Full Text] [Related]
2. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.
Griesshammer M; Klippel S; Strunck E; Temerinac S; Mohr U; Heimpel H; Pahl HL
Ann Hematol; 2004 Jun; 83(6):364-70. PubMed ID: 15034760
[TBL] [Abstract][Full Text] [Related]
3. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
4. Detection of abnormalities of PRV-1, TPO, and c-MPL genes detected by fluorescence in situ hybridization in essential thrombocythemia.
Puigdecanet E; Espinet B; Villa O; Florensa L; Besses C; Serrano S; Solé F
Cancer Genet Cytogenet; 2006 May; 167(1):39-42. PubMed ID: 16682284
[TBL] [Abstract][Full Text] [Related]
5. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia.
Teofili L; Pierconti F; Di Febo A; Maggiano N; Vianelli N; Ascani S; Rossi E; Pileri S; Leone G; Larocca LM; De Stefano V
Blood; 2002 Jul; 100(2):714-7. PubMed ID: 12091373
[TBL] [Abstract][Full Text] [Related]
6. Current evaluation of the clinical, diagnostic, and therapeutic usefulness of prv-1 and c-mpl markers in polycythemia vera and essential thrombocythemia.
Pahl HL
Clin Adv Hematol Oncol; 2004 Apr; 2(4):202, 204. PubMed ID: 16163180
[No Abstract] [Full Text] [Related]
7. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
[TBL] [Abstract][Full Text] [Related]
8. The effect of the JAK2 V617F mutation on PRV-1 expression.
Mnjoyan Z; Yoon D; Li J; Delhommeau F; Afshar-Kharghan V
Haematologica; 2006 Mar; 91(3):411-2. PubMed ID: 16503546
[TBL] [Abstract][Full Text] [Related]
9. Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines.
Dillon M; Minear J; Johnson J; Lannutti BJ
Leuk Res; 2008 May; 32(5):811-9. PubMed ID: 17980909
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia.
Griesshammer M
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):372-80. PubMed ID: 16810613
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic approaches to polycythemia vera in 2004.
Pahl HL
Expert Rev Mol Diagn; 2004 Jul; 4(4):495-502. PubMed ID: 15225097
[TBL] [Abstract][Full Text] [Related]
12. PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia.
Vannucchi AM; Grossi A; Pancrazzi A; Antonioli E; Guglielmelli P; Balestri F; Biscardi M; Bulgarelli S; Longo G; Graziano C; Gugliotta L; Bosi A
Br J Haematol; 2004 Oct; 127(2):214-9. PubMed ID: 15461629
[TBL] [Abstract][Full Text] [Related]
13. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.
Kralovics R; Buser AS; Teo SS; Coers J; Tichelli A; van der Maas AP; Skoda RC
Blood; 2003 Sep; 102(5):1869-71. PubMed ID: 12730106
[TBL] [Abstract][Full Text] [Related]
14. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia.
Li J; Xia Y; Kuter DJ
Br J Haematol; 2000 Dec; 111(3):943-53. PubMed ID: 11122159
[TBL] [Abstract][Full Text] [Related]
15. Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia.
Johansson P; Ricksten A; Wennström L; Palmqvist L; Kutti J; Andréasson B
Br J Haematol; 2003 Nov; 123(3):513-6. PubMed ID: 14617016
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic markers in essential thrombocythemia.
Gale RE
Curr Hematol Rep; 2003 May; 2(3):242-7. PubMed ID: 12901346
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
18. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.
Passamonti F; Pietra D; Rumi E; Arcaini L; Della Porta MG; Malcovati L; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2005 May; 19(5):888-9. PubMed ID: 15744342
[No Abstract] [Full Text] [Related]
19. The PRV-1 gene expression in essential thrombocythemia.
Teofili L; Martini M; Guidi F; Venditti D; Leone G; Larocca ML
Blood; 2004 Nov; 104(9):2995-6. PubMed ID: 15498866
[No Abstract] [Full Text] [Related]
20. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.
Bellosillo B; Besses C; Florensa L; Solé F; Serrano S
Leukemia; 2006 Apr; 20(4):736-7. PubMed ID: 16453004
[No Abstract] [Full Text] [Related]
[Next] [New Search]
